Nothing Special   »   [go: up one dir, main page]

EE200200357A - Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid - Google Patents

Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid

Info

Publication number
EE200200357A
EE200200357A EEP200200357A EEP200200357A EE200200357A EE 200200357 A EE200200357 A EE 200200357A EE P200200357 A EEP200200357 A EE P200200357A EE P200200357 A EEP200200357 A EE P200200357A EE 200200357 A EE200200357 A EE 200200357A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
drug substance
providing increased
increased concentrations
compositions providing
Prior art date
Application number
EEP200200357A
Other languages
English (en)
Estonian (et)
Inventor
Christian Babcock Walter
John Curatolo William
Thomas Friesen Dwayne
Alan Lorenz Douglas
Alan Schriver Nightingale James
Mysore Shanker Ravi
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200357A publication Critical patent/EE200200357A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200200357A 1999-12-23 2000-12-01 Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid EE200200357A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17184199P 1999-12-23 1999-12-23
PCT/IB2000/001787 WO2001047495A1 (en) 1999-12-23 2000-12-01 Pharmaceutical compositions providing enhanced drug concentrations

Publications (1)

Publication Number Publication Date
EE200200357A true EE200200357A (et) 2003-10-15

Family

ID=22625351

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200357A EE200200357A (et) 1999-12-23 2000-12-01 Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid

Country Status (39)

Country Link
US (6) US8026286B2 (es)
EP (3) EP1239835B1 (es)
JP (2) JP2003518485A (es)
KR (1) KR100558239B1 (es)
CN (1) CN1402629A (es)
AP (1) AP2002002552A0 (es)
AR (1) AR027065A1 (es)
AU (1) AU784340B2 (es)
BG (1) BG106764A (es)
BR (1) BR0016555A (es)
CA (1) CA2395331C (es)
CO (1) CO5261563A1 (es)
CR (1) CR6654A (es)
CZ (1) CZ20022047A3 (es)
DZ (1) DZ3227A1 (es)
EA (1) EA006402B1 (es)
EC (1) ECSP003847A (es)
EE (1) EE200200357A (es)
GE (1) GEP20053427B (es)
GT (1) GT200000219A (es)
HR (1) HRP20020531A2 (es)
HU (1) HUP0204372A3 (es)
IL (1) IL149186A0 (es)
IS (1) IS6344A (es)
MA (1) MA26853A1 (es)
MX (1) MXPA02006324A (es)
NO (1) NO20022998L (es)
OA (1) OA12124A (es)
PA (1) PA8508701A1 (es)
PE (1) PE20010977A1 (es)
PL (1) PL357470A1 (es)
SK (1) SK8562002A3 (es)
SV (1) SV2002000248A (es)
TN (1) TNSN00252A1 (es)
TR (1) TR200201617T2 (es)
UY (1) UY26496A1 (es)
WO (1) WO2001047495A1 (es)
YU (1) YU43702A (es)
ZA (1) ZA200204962B (es)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
EE200200357A (et) * 1999-12-23 2003-10-15 Pfizer Products Inc. Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
GT200100039A (es) 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
US20030060422A1 (en) * 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US7429238B2 (en) * 2001-10-15 2008-09-30 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
EP1461044A4 (en) * 2001-12-03 2007-06-13 Novacea Inc PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE COMPOUNDS OF VITAMIN D
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
ATE403432T1 (de) 2002-02-01 2008-08-15 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester- transferproteininhibitors
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
CA2474835A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
WO2003082262A2 (en) * 2002-03-28 2003-10-09 Synthon B.V. Compositions of venlafaxine base
EP1485344A1 (en) 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
AR039164A1 (es) 2002-03-28 2005-02-09 Synthon Bv Sales de venlafaxina de baja solubilidad en agua
PT1530457E (pt) 2002-08-12 2009-11-06 Bend Res Inc Composições farmacêuticas de fármacos na forma semi-ordenada e de polímeros
WO2004027027A2 (en) 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Kdl株式会社 ピリドン誘導体の溶液状医薬組成物
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
MXPA06000178A (es) * 2003-07-01 2006-04-11 Pharmacia & Upjohn Co Llc Solidos modulados en la fase de difusion.
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
ATE540671T1 (de) * 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US20050112204A1 (en) * 2003-11-25 2005-05-26 Pfizer Inc. Pharmaceutical formulations
BRPI0418330A (pt) 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
WO2005089511A2 (en) * 2004-03-19 2005-09-29 Transform Pharmaceuticals, Inc. Novel pharmaceutical forms, and methods of making and using the same
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
US8158138B1 (en) * 2004-05-20 2012-04-17 Fougera Pharmaceuticals, Inc. Urea compositions and their methods of manufacture
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
CN101123951A (zh) 2004-08-31 2008-02-13 辉瑞产品公司 包括低溶解性药物和聚合物的药物剂型
SI2415484T1 (sl) * 2004-09-17 2014-10-30 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
EP1844078B1 (en) * 2005-02-03 2016-09-28 Bend Research, Inc Pharmaceutical compositions with enhanced performance
PL1848431T3 (pl) 2005-02-09 2016-08-31 Santen Pharmaceutical Co Ltd Ciekłe formulacje do leczenia chorób lub stanów
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20070287719A1 (en) * 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
WO2007014393A2 (en) * 2005-07-28 2007-02-01 Isp Investments Inc. Amorphous efavirenz and the production thereof
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
CN103127100A (zh) 2006-03-23 2013-06-05 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂和方法
US8900619B2 (en) 2006-08-24 2014-12-02 Boston Scientific Scimed, Inc. Medical devices for the release of therapeutic agents
AU2007300071A1 (en) * 2006-09-27 2008-04-03 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
US10189957B2 (en) * 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
WO2009010837A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
BRPI1010739A2 (pt) 2009-06-16 2016-03-15 Bristol Myers Squibb Co formas de dosagens de apixaban.
WO2011068403A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts
KR101809484B1 (ko) 2009-12-03 2017-12-15 알콘 리서치, 리미티드 카복시비닐 폴리머를 포함하는 나노입자 현탁액
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
US20120015913A1 (en) * 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AU2012204462A1 (en) 2011-01-05 2013-07-11 Hospira, Inc. Spray drying vancomycin
AU2012225459A1 (en) 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
JP5879803B2 (ja) * 2011-08-08 2016-03-08 ライオン株式会社 固形医薬組成物、その製造方法及び医薬製剤
EP2854816B1 (en) 2012-05-31 2020-07-08 Merck Sharp & Dohme Corp. Solid dosage formulations of an orexin receptor antagonist
AU2013323435C1 (en) 2012-09-26 2018-04-12 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban liquid formulations
EP2908808A1 (en) 2012-10-18 2015-08-26 Abbvie Inc. Formulations of pyrimidinedione derivative compounds
JP6456849B2 (ja) 2013-03-01 2019-01-23 ハーキュリーズ・インコーポレーテッドHercules Incorporated 高められた性能及び改善された加工性を有する医薬組成物
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9918939B2 (en) * 2013-07-30 2018-03-20 Gilead Connecticut, Inc. Formulation of Syk inhibitors
AU2014306698A1 (en) 2013-08-12 2016-01-28 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
TW201613579A (en) 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
KR102117677B1 (ko) * 2018-03-08 2020-06-01 (주)이엘티사이언스 용해도가 개선된 축산용 삼종염 소독제 복합조성물
WO2019175657A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
CA3094591C (en) 2018-04-06 2024-03-26 Capsugel Belgium Nv Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
WO2019220282A1 (en) * 2018-05-14 2019-11-21 Capsugel Belgium Nv Solid dosage forms with high active agent loading
KR20210034047A (ko) 2018-07-19 2021-03-29 임펠 뉴로파마 인코포레이티드 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달
JP7538113B2 (ja) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ,インコーポレーテッド 補体d因子の医学的障害の治療のための医薬化合物
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
JP2022516437A (ja) * 2018-12-19 2022-02-28 ガレクト バイオテック エービー 5-ブロモピリジン-3-イル3-デオキシ-3-[4-(3,4,5-トリフルオロフェニル)-1H-1,2,3-トリアゾール-1-イル]-1-チオ-α-D-ガラクトピラノシドの非晶質形態
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
JP7188364B2 (ja) * 2019-11-25 2022-12-13 トヨタ自動車株式会社 車椅子乗客拘束構造
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
KR20240053626A (ko) * 2021-09-05 2024-04-24 타이알엑스, 아이엔씨. 강화된 sn-38 용해성 및 경구 흡수성을 갖는 제형
WO2024012361A1 (zh) * 2022-07-11 2024-01-18 江苏恩华药业股份有限公司 阿法沙龙脂肪乳注射液及其制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344934A (en) 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
US4321253A (en) 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
DE3224619A1 (de) 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
FR2525108B1 (fr) 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
US4933360A (en) 1983-03-16 1990-06-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel chlorthalidone process and product
US4517179A (en) 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1187751B (it) 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
IE63321B1 (en) 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
JPS6314724A (ja) 1986-07-08 1988-01-21 Tooa Eiyoo Kk プラゾシン製剤
PH26518A (en) 1987-11-11 1992-08-07 Fujisawa Pharmaceutical Co A novel pharmaceutical composition comprising exifone and water-soluble polymer
IE60383B1 (en) 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
JP2528706B2 (ja) * 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
US5368864A (en) 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
JPH02149518A (ja) 1988-11-30 1990-06-08 Nikken Chem Co Ltd 経口投与用薬剤
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
CA2020654A1 (en) * 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5035897A (en) 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
JP2939491B2 (ja) * 1989-12-11 1999-08-25 株式会社アドバンス 機能性食品
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
KR0172134B1 (ko) 1990-07-19 1999-02-01 오오쓰까 아끼히코 고형 제제
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
EP0482948A1 (en) 1990-10-26 1992-04-29 Asahi Kasei Kogyo Kabushiki Kaisha A medicament composition containing 6-substituted alkoxy quinoxaline derivative and its production
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
JP2881519B2 (ja) 1991-07-09 1999-04-12 中塚工業 株式会社 艶消し立体模様箔糸原反の製造法
US5225204A (en) 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
DK89592D0 (da) 1992-07-07 1992-07-07 Helle Broendsted Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
JPH06128147A (ja) * 1992-10-20 1994-05-10 Masayasu Sugihara 水難溶性薬品の溶解性改善方法およびそれにより得られた薬品組成物
JPH06314724A (ja) 1993-04-28 1994-11-08 Hitachi Cable Ltd 半導体素子搭載用両面配線基板,及びそれを用いた半導 体装置
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5972383A (en) 1994-03-02 1999-10-26 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
AU4314196A (en) 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
JP3145409B2 (ja) * 1995-03-24 2001-03-12 フォーカル, インコーポレイテッド 活性酸素阻害剤の制御送達を用いる癒着の低減
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
JP3938938B2 (ja) 1995-07-26 2007-06-27 協和醗酵工業株式会社 キサンチン誘導体の固体分散体または固体分散体製剤
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
DE19531684A1 (de) 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JPH09309828A (ja) 1996-03-18 1997-12-02 Eisai Co Ltd 溶解を改善した薬剤組成物
NZ332219A (en) * 1996-05-07 2005-02-25 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (ziprasidone), its preparation and its use as dopamine D2 antagonist
JPH107558A (ja) 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
EP0826685A1 (en) * 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US5977158A (en) 1996-11-28 1999-11-02 Novo Nordisk A/S Pharmaceutical formulations comprising levormeloxifene compounds
SK181099A3 (en) 1997-07-01 2000-07-11 Pfizer Prod Inc Solubilized sertraline compositions
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
HN1998000115A (es) 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
CA2273272C (en) * 1997-10-07 2004-09-21 Fuisz Technologies Ltd. Immediate release drug delivery forms
US6110502A (en) * 1998-02-19 2000-08-29 Mcneil-Ppc, Inc. Method for producing water dispersible sterol formulations
PL200163B1 (pl) 1998-06-11 2008-12-31 Upjohn Co Kompozycja farmaceutyczna w postaci tabletki o nieprzedłużonym działaniu i sposób jej wytwarzania
ES2157731B1 (es) 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
JP2002525311A (ja) 1998-10-01 2002-08-13 エラン ファーマ インターナショナル,リミティド 徐放性ナノ粒子組成物
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TR200102297T1 (tr) 1999-12-08 2002-03-21 Pharmacia Corporation Valdekoksib bileçimler.
DK1150959T3 (da) 1999-12-08 2008-06-02 Pharmacia Corp Faststoftilstandsform af Celecoxib, der har foröget biotilgængelighed
EE200200357A (et) * 1999-12-23 2003-10-15 Pfizer Products Inc. Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
AR027656A1 (es) * 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa

Also Published As

Publication number Publication date
US9457095B2 (en) 2016-10-04
DZ3227A1 (fr) 2001-07-05
BR0016555A (pt) 2002-09-17
GEP20053427B (en) 2005-01-25
TNSN00252A1 (fr) 2002-05-30
UY26496A1 (es) 2001-07-31
US8501231B2 (en) 2013-08-06
CR6654A (es) 2004-01-14
IL149186A0 (en) 2002-11-10
CO5261563A1 (es) 2003-03-31
CZ20022047A3 (cs) 2003-09-17
HUP0204372A2 (en) 2003-05-28
PA8508701A1 (es) 2002-12-11
EP1712222A3 (en) 2012-06-20
US20020006443A1 (en) 2002-01-17
US8980321B2 (en) 2015-03-17
BG106764A (bg) 2003-03-31
ZA200204962B (en) 2003-09-29
AU784340B2 (en) 2006-03-16
KR20020068061A (ko) 2002-08-24
WO2001047495A1 (en) 2001-07-05
AP2002002552A0 (en) 2002-06-30
KR100558239B1 (ko) 2006-03-10
GT200000219A (es) 2002-06-14
EP1712222A2 (en) 2006-10-18
CN1402629A (zh) 2003-03-12
US20130345236A1 (en) 2013-12-26
AU1409101A (en) 2001-07-09
HRP20020531A2 (en) 2004-02-29
AR027065A1 (es) 2003-03-12
HUP0204372A3 (en) 2004-06-28
SV2002000248A (es) 2002-07-03
PL357470A1 (en) 2004-07-26
US20150190518A1 (en) 2015-07-09
IS6344A (is) 2002-04-16
EA200200431A1 (ru) 2002-10-31
MA26853A1 (fr) 2004-12-20
US8202912B2 (en) 2012-06-19
JP2008101004A (ja) 2008-05-01
US20110294902A1 (en) 2011-12-01
OA12124A (en) 2006-05-05
EA006402B1 (ru) 2005-12-29
US8026286B2 (en) 2011-09-27
US8796341B2 (en) 2014-08-05
EP1239835B1 (en) 2013-03-20
EP1738749A1 (en) 2007-01-03
SK8562002A3 (en) 2003-10-07
NO20022998D0 (no) 2002-06-21
US20140322325A1 (en) 2014-10-30
NO20022998L (no) 2002-08-15
CA2395331C (en) 2009-01-06
PE20010977A1 (es) 2001-09-28
US20120259022A1 (en) 2012-10-11
TR200201617T2 (tr) 2002-10-21
EP1239835A1 (en) 2002-09-18
MXPA02006324A (es) 2002-12-13
YU43702A (sh) 2004-11-25
ECSP003847A (es) 2001-06-11
JP2003518485A (ja) 2003-06-10
CA2395331A1 (en) 2001-07-05

Similar Documents

Publication Publication Date Title
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
NO20020464L (no) Flerkomponents farmasöytisk doseringsform
NO20015175D0 (no) Farmasöytisk sammensetning
FR2795324B1 (fr) Compositions pharmaceutiques stabilisees
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
ITTO20010008A0 (it) Formulazione farmaceutica
FI991485A (fi) Uusi farmaseuttinen koostumus
PT1242087E (pt) Composicoes farmaceuticas
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
ATE317260T1 (de) Pharmazeutische formulierungen mit platinderivaten
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
EE200100259A (et) Moksifloksatsiini farmatseutiline preparaat
EE05020B1 (et) Glburiidi ravimkoostis
ATE401908T1 (de) Pharmazeutische zusammensetzungen von erythropoietin
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
ATE383868T1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
FR2802423B1 (fr) Compositions pharmaceutiques
NO20014926L (no) Farmasöytiske forbindelser
NO20021898L (no) Farmasoytisk sammensetning inneholdende ciclesonid for applikasjon til mukosa
EE200300135A (et) Trüptamiini derivaadid ja analoogsed ühendid ningneid sisaldavad farmatseutilised preparaadid
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20004816D0 (no) Ny farmasøytisk formulering